Download MendeleyStructure-Based Design and Identification of FT-2102 (Olutasidenib), a Potent Mutant-Selective IDH1 Inhibitor.
Caravella, J.A., Lin, J., Diebold, R.B., Campbell, A.M., Ericsson, A., Gustafson, G., Wang, Z., Castro, J., Clarke, A., Gotur, D., Josephine, H.R., Katz, M., Kershaw, M., Yao, L., Toms, A.V., Barr, K.J., Dinsmore, C.J., Walker, D., Ashwell, S., Lu, W.(2020) J Med Chem 63: 1612-1623
- PubMed: 31971798
- DOI: https://doi.org/10.1021/acs.jmedchem.9b01423
- Primary Citation of Related Structures:
6U4J - PubMed Abstract:
Inhibition of mutant IDH1 is being evaluated clinically as a treatment option for oncology. Here we describe the structure-based design and optimization of quinoline lead compounds to identify FT-2102 , a potent, orally bioavailable, brain penetrant, and selective mIDH1 inhibitor. FT-2102 has excellent ADME/PK properties and reduces 2-hydroxyglutarate levels in an mIDH1 xenograft tumor model. This compound has been selected as a candidate for clinical development in hematologic malignancies, solid tumors, and gliomas with mIDH1.
Organizational Affiliation:
FORMA Therapeutics, Inc. , 500 Arsenal Street, Suite 100 , Watertown , Massachusetts 02472 , United States.
